Drug trials
Global partnerships to meet the dementia challenge
We’re committed to backing initiatives that bring us closer to delivering effective treatments for people with dementia, that’s why we’ve joined the CAMD.
The failure rate of clinical trials for Alzheimer’s – why we need to raise our game
We need to learn from recent failings in clinical trials and inform research feeding back into the early drug development pipeline.
What’s the point of a blood test for Alzheimer’s?
Why would we need to diagnose the disease before those symptoms appeared? The answer lies in the search for new treatments.
When will there be new Alzheimer’s treatments?
We look at the most promising developments in the treatments of Alzheimer’s disease.
What to expect from the next five years of dementia research
Alzheimer’s Research UK’s Director of Research Dr Eric Karran spoke recently about his hopes for the development of new Alzheimer’s treatments and dementia research.
What difference can you make to dementia research?
Dr Laura Phipps blogs on how you can help with the research effort in dementia.
Placebo Tea
In this short piece on the placebo effect I’m going to describe why we need clinical trials to develop new Alzheimer’s treatments. And cups of tea.
When is a failed clinical trial not a failure?
The latest results from the Elan dementia trials have proved one of the more interesting dementia research stories of the summer.
Right drug, right patient, right time
This month we’ll be at the political party conferences urging all parties to continue to back dementia research. With no new drugs since 2003, and those in existence only showing modest efficacy, we desperately need new treatments that can delay the onset, slow the progression and manage the symptoms of dementia.
